BioSpace News Archive

The increasing adoption of orphan drugs and the rising popularity of generics in the medical sector is a prime factor augmenting the growth of the global tablet coatings market.

The increasing popularity of less complicated surgical treatments for preventing any risk of infection among patients is prognosticated to augment the growth of the global dental obturators market.

Scipher Medicine, a precision immunology company matching patients with their most effective therapies, announced the appointment of John Strumbos, Ph.D., MBA as Chief Financial Officer.

EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has been granted patent GB 2576304 for its novel method for DNA data storage and retrieval.

Bio innovation studio behind liquid biopsy companies LiquidLung, HepGene, and Mammogen, comes out of stealth with eight clinical-ready diagnostics

Camber Spine, a leading innovator in spine and medical technologies, has initiated the full national launch of its SPIRA-P Posterior Lumbar Spacer and SPIRA-T Oblique Posterior Lumbar Spacer devices.

Today, the U.S Food and Drug Administration issued for public comment two draft guidance documents that, if finalized, will help manufacturers of animal cells, tissues, and cell- and tissue-based products (ACTPs) understand current good manufacturing practice requirements (CGMPs) for new animal drugs under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

AB Science SA (Euronext - FR0010557264 - AB) today announced that its clinical trial with AB8939 in adult patients with relapsed/refractory acute myeloid leukemia (AML) has been approved by Health Canada.

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi® (ruxolitinib) for treatment of chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced positive preclinical data demonstrating that ELI-005, a protein subunit vaccine containing the lymph node-targeted Amphiphile-CpG adjuvant (AMP-CpG), induces potent cellular and humoral immunity to SARS-CoV-2 at the 2021 Vaccines Summit.